Potential Treatment of Cardiac Hypertrophy and Heart Failure by Inhibiting the Sarcolemmal Binding of Phospholipase Cβ1b

Author(s): E.A. Woodcock, D.R. Grubb, P. Iliades

Journal Name: Current Drug Targets

Volume 11 , Issue 8 , 2010

Become EABM
Become Reviewer


Heart failure, the common end-point of many cardiac diseases, is a major contributor to mortality and morbidity and contributes considerably to health care costs. Current treatment regimens include β-adrenergic antagonists, angiotensin converting enzyme inhibitors, and inotropic agents are used by some patients. Studies in experimental animals have demonstrated that inhibition of signaling pathways downstream of the heterotrimeric G protein Gq reduces ventricular hypertrophy and protects from the development of heart failure. However, targets identified, to date, have been limited by a lack of tissue specificity. In cardiomyocytes, Gq activates only one splice variant of one subtype of phospholipase Cβ, specifically phospholipase Cβ1b (PLCβ1b) and PLCβ1b is responsible for Gq mediated hypertrophic and apoptotic responses. PLCβ1b targets the sarcolemma via its unique C-terminal sequence and its activation can be inhibited by expressing the C-terminal sequence to compete for sarcolemmal binding. Inhibition of PLCβ1b by the C-terminal peptide reduces hypertrophic responses in cardiomyocytes. We present the evidence that inhibition of the sarcolemmal association of PLCβ1b provides a cardiac-specific target for the development of drugs to reduce pathological cardiac hypertrophy and thereby to reduce the burden of heart failure.

Keywords: Cardiomyocyte, hypertrophy, apoptosis, mini-gene inhibitor, C-terminal peptide, proline-rich domains, phospholipase C, Gq

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2010
Page: [1032 - 1040]
Pages: 9
DOI: 10.2174/138945010791591331
Price: $65

Article Metrics

PDF: 11